The endothelial cytoskeleton as a target of electroporation-based therapies

Molecular Cancer Therapeutics

Volumn 5, Issue 12, 2006, Pages 3145-3152

  Kanthou, Chryso ^a   Kranjc, Simona ^b   Sersa, Gregor ^b   Tozer, Gill ^a   Zupanic, Anze ^b   Cemazar, Maja ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; BETA TUBULIN; CYTOSKELETON PROTEIN; F ACTIN; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; HEAT SHOCK PROTEIN 70; MYOSIN LIGHT CHAIN; VASCULAR ENDOTHELIAL CADHERIN; VIMENTIN;

ACTIN FILAMENT; ARTICLE; BLOOD FLOW; CELL DAMAGE; CELL JUNCTION; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; CONTROLLED STUDY; CYTOSKELETON; ELECTRIC POTENTIAL; ELECTROPORATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MICROFILAMENT; MICROTUBULE ASSEMBLY; MONOLAYER CULTURE; PRIORITY JOURNAL; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

ACTINS; ANTIGENS, CD; CADHERINS; CYTOSKELETON; ELECTROPORATION; ENDOTHELIAL CELLS; HUMANS; INTERMEDIATE FILAMENTS; MICROFILAMENTS; MICROTUBULES; MYOSINS; NEOPLASMS;

EID: 33846220232     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0410     Document Type: Article

References (40)

1. Mir LM. Therapeutic perspectives of in vivo cell electropermeabilization. Bioelectrochemistry 2000;53:1-10.
2. Belehradek J, Jr., Orlowski S, Poddevin B, Paoletti C, Mir LM. Electrochemotherapy of spontaneous mammary tumours in mice. Cancer 1991;27:73-6.
3. Sersa G, Cemazar M, Miklavcic D. Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice. Cancer Res 1995;55:3450-5.
4. Mir LM, Orlowski S. Mechanisms of electrochemotherapy. Adv Drug Deliv Rev 1999;35:107-18.
5. Cemazar M, Sersa G, Wilson J, et al. Effective gene transfer to solid tumors using different nonviral gene delivery techniques: electroporation, liposomes and integrin-targeted vector. Cancer Gene Ther 2002;9: 399-406.
6. Heller R, Jaroszeski M, Atkin A, et al. In vivo gene electroinjection and expression in rat liver. FEBS Lett 1996;389:225-8.
7. Rols MP, Delteil C, Golzio M, Dumond P, Cros S, Teissie J. In vivo electrically mediated protein and gene transfer in murine melanoma. Nat Biotechnol 1998;16:168-71.
8. Mir LM, Moller PH, Andre F, Gehl J. Electric pulse-mediated gene delivery to various animal tissues. Adv Genet 2005;54:83-114.
9. Babiuk LA, Pontarollo R, Babiuk S, Loehr B, van Drunen Little-van den Hurk S. Induction of immune responses by DNA vaccines in large animals. Vaccine 2003;21:649-85.
10. Byrne CM, Thompson JF. Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors. Expert Rev Anticancer Ther 2006;6:671-8.
11. Belehradek J, Jr., Orlowski S, Ramirez LH, Pron G, Poddevin B, Mir LM. Electropermeabilization of cells in tissues assessed by the qualitative and quantitative electroloading of bleomycin. Biochim Biophys Acts 1994; 1190:155-63.
12. Cemazar M, Miklavcic D, Scancar J, Dolzan V, Golouh R, Sersa G. Increased platinum accumulation in SA-1 tumour cells after in vivo electrochemotherapy with cisplatin. Br J Cancer 1999;79:1386-91.
13. Cemazar M, Parkins CS, Holder AL, Chaplin DJ, Tozer GM, Sersa G. Electroporation of human microvascular endothelial cells: evidence for an anti-vascular mechanism of electrochemotherapy. Br J Cancer 2001;84: 565-70.
14. Sersa G, Cemazar M, Miklavcic D, Chaplin DJ. Tumor blood flow modifying effect of electrochemotherapy with bleomycin. Anticancer Res 1999;19:4017-22.
15. Sersa G, Cemazar M, Parkins CS, Chaplin DJ. Tumour blood flow changes induced by application of electric pulses. Eur J Cancer 1999;35: 672-7.
16. Sersa G, Krzic M, Sentjurc M, et al. Reduced blood flow and oxygenation in SA-1 tumours after electrochemotherapy with cisplatin. Br J Cancer 2002;87:1047-54.
17. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 1990;9:267-82.
18. Kanthou C, Tozer GM. The vascular disrupting agent combretastatin A-4 phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002;99: 2060-9.
19. Tozer GM, Prise VE, Wilson J, et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 1999;59:1626-34.
20. Tozer GM, Prise VE, Wilson J, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001;61:6413-22.
21. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5:423-35.
22. Wojciak-Stothard B, Ridley AJ. Rho GTPases and the regulation of endothelial permeability. Vasc Pharmacol 2002;39:187-99.
23. Bazzoni G, Dejana E. Endothelial cell-to-cell junctions: molecular organisation and role in vascular homeostasis. Physiol Rev 2004;84: 869-901.
24. Kohama K, Ye LH, Hayakawa K, Okagaki T. Myosin light chain kinase: an actin-binding protein that regulates an ATP-dependent interaction with myosin. Trends Pharmacol Sci 1996;17:284-7.
25. Ridley AJ, Hall A. The small GTP-binding protein Rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 1992;70:389-99.
26. Amano M, Ito M, Kimura K, et al. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem 1996;271: 20246-9.
27. van Nieuw Amerongen GP, van Hinsbergh VW. Cytoskeletal effects of rho-like small guanine nucleotide-binding proteins in the vascular system. Arterioscler Thromb Vasc Biol 2001;21:300-11.
28. Teissie J, Rols MP. Manipulation of cell cytoskeleton affects the lifetime of cell membrane electropermeabilization. Ann N Y Acad Sci 1994; 720:98-110.
29. Harkin DG, Hay ED. Effects of electroporation on the tubulin cytoskeleton and directed migration of corneal fibroblasts cultured within collagen matrices. Cell Motil Cytoskeleton 1996;35:345-57.
30. Gehl J, Geertsen PF. Efficient palliation of haemorrhaging malignant melanoma skin metastases by electrochemotherapy. Melanoma Res 2000; 10:585-9.
31. Gehl J, Skovsgaard T, Mir LM. Vascular reactions to in vivo electroporation: characterization and consequences for drug and gene delivery. Biochim Biophys Acts 2002;1569:51-8.
32. Kranjc S, Cemazar M, Grosel A, Scancar J, Sersa G. Electroporation of LPB sarcoma cells in vitro and tumors in vivo increases the radiosensitizing effect of cisplatin. Anticancer Res 2003;23:275-81.
33. Galbraith SM, Chaplin DJ, Lee F, et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 2001;21: 93-102.
34. Amos LA, Schlieper D. Microtubules and maps. Adv Protein Chem 2005;71:257-98.
35. Bokoch GM, Bohl BP, Chuang TH. Guanine nucleotide exchange regulates membrane translocation of Rac/Rho GTP-binding proteins. J Biol Chem 1994;269:31674-9.
36. Wilson L, Jordan MA. Microtubule dynamics: taking aim at a moving target. Chem Biol 1995;2:569-73.
37. Blangero C, Rols MP, Teissie J. Cytoskeletal reorganization during electric-field-induced fusion of Chinese hamster ovary cells grown in monolayers. Biochim Biophys Acta 1989;981:295-302.
38. Dressel R, Baraki H, Langer F, Gunther E. Reduced susceptibility of electroporated tumor cell lines to killing by cytotoxic lymphocytes. Biochem Biophys Res Commun 1998;250:259-63.
39. Susil R, Semrov D, Miklavcic D. Electric field-induced transmembrane potential depends on cell density and organization. Electro Magnetobiol 1998;17:391-9.
40. Sugar IP, Lindesay J, Schmukler RE. Phenomenological theory of low-voltage electroporation. Electric field calculations. J Phys Chem B 2003; 107:3862-70.